R. Abdelrahman, M. Sivarajah, A. Thiemermann, and C. , Beneficial effects of PPAR-? ligands in ischemia?reperfusion injury, inflammation and shock, Cardiovascular Research, vol.65, issue.4, pp.772-781, 2005.
DOI : 10.1016/j.cardiores.2004.12.008

S. Aggarwal, Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17, Journal of Biological Chemistry, vol.66, issue.3, pp.1910-1914, 2003.
DOI : 10.4049/jimmunol.167.12.6957

M. Ahmadian, PPAR?? signaling and metabolism: the good, the bad and the future, Nature Medicine, vol.40, issue.5, pp.557-566, 2013.
DOI : 10.1093/nar/gks595

T. Akune, PPAR ?? insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors, Journal of Clinical Investigation, vol.113, issue.6, pp.846-855, 2004.
DOI : 10.1172/JCI200419900

URL : http://europepmc.org/articles/pmc362117?pdf=render

E. Assier, M. Boissier, and J. Dayer, Interleukin-6: From identification of the cytokine to development of targeted treatments, Joint Bone Spine, vol.77, issue.6, pp.532-536, 2010.
DOI : 10.1016/j.jbspin.2010.07.007

O. Astapova and T. Leff, PPAR? mutations, lipodystrophy and diabetes. Hormone molecular biology and clinical investigation, pp.63-70, 2014.
DOI : 10.1515/hmbci-2014-0033

D. Auboeuf, Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients, Diabetes, vol.46, issue.8, pp.461319-1327, 1997.
DOI : 10.2337/diabetes.46.8.1319

Y. Barak, PPAR?? Is Required for Placental, Cardiac, and Adipose Tissue Development, Molecular Cell, vol.4, issue.4, pp.585-595, 1999.
DOI : 10.1016/S1097-2765(00)80209-9

D. Baram, Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. The journal of Immunology, pp.4008-4016, 2001.

S. Barete, Systemic mastocytosis and bone involvement in a cohort of 75 patients, Annals of the Rheumatic Diseases, vol.69, issue.10, pp.1838-1841, 2010.
DOI : 10.1136/ard.2009.124511

URL : https://hal.archives-ouvertes.fr/hal-00528144

J. Berger and D. E. Moller, The mechanisms of action of PPARs. The mechanisms of action of PPARs, pp.409-435, 2002.

E. Bettelli, T. Korn, and V. K. Kuchroo, Th17: the third member of the effector T cell trilogy, Current Opinion in Immunology, vol.19, issue.6, pp.652-657, 2007.
DOI : 10.1016/j.coi.2007.07.020

M. Biosse-duplan, Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. The American journal of pathology, pp.1426-1434, 2009.

S. C. Bischoff and G. Sellge, Mast Cell Hyperplasia: Role of Cytokines, International Archives of Allergy and Immunology, vol.127, issue.2, pp.118-122, 2002.
DOI : 10.1159/000048181

D. Bishop-bailey and J. Wray, Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation, Prostaglandins & Other Lipid Mediators, vol.71, issue.1-2, pp.1-22, 2003.
DOI : 10.1016/S0090-6980(03)00003-0

M. Boissier, Cell and cytokine imbalances in rheumatoid synovitis, Joint Bone Spine, vol.78, issue.3, pp.230-234, 2011.
DOI : 10.1016/j.jbspin.2010.08.017

K. Bordji, Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes, The Journal of biological chemistry, issue.16, pp.27512243-12250, 2000.

J. Bowes and A. Barton, Recent advances in the genetics of RA susceptibility, Rheumatology, vol.47, issue.4, pp.399-402, 2008.
DOI : 10.1093/rheumatology/ken005

S. Boyault, , but not troglitazone, modulates IL-1?? effects in human chondrocytes by inhibiting NF-??B and AP-1 activation pathways, FEBS Letters, vol.43, issue.1, pp.24-30, 2001.
DOI : 10.1021/jm990554g

B. F. Boyce and L. Xing, Functions of RANKL/RANK/OPG in bone modeling and remodeling, Archives of Biochemistry and Biophysics, vol.473, issue.2, pp.139-146, 2008.
DOI : 10.1016/j.abb.2008.03.018

B. F. Boyce and L. Xing, The RANKL/RANK/OPG pathway, Current Osteoporosis Reports, vol.83, issue.suppl1, pp.98-104, 2007.
DOI : 10.1007/s11914-007-0024-y

O. Braissant, Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat., Endocrinology, vol.137, issue.1, pp.354-366, 1996.
DOI : 10.1210/endo.137.1.8536636

M. G. Buckley, -tryptase, Histamine and Eosinophil Cationic Protein in Synovial Fluid, Clinical Science, vol.93, issue.4, pp.363-370, 1979.
DOI : 10.1042/cs0930363

G. R. Burmester, E. Feist, and T. Dörner, Emerging cell and cytokine targets in rheumatoid arthritis, Nature Reviews Rheumatology, vol.71, issue.2, pp.77-88, 2013.
DOI : 10.1038/nrneph.2012.141

G. Caron, Histamine Polarizes Human Dendritic Cells into Th2 Cell-Promoting Effector Dendritic Cells, The Journal of Immunology, vol.167, issue.7, pp.3682-3686, 2001.
DOI : 10.4049/jimmunol.167.7.3682

A. Carroll-portillo, Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation, The Journal of Cell Biology, vol.68, issue.5, pp.851-864, 2015.
DOI : 10.1083/jcb.201412074.dv

E. Castillero, Fenofibrate, a PPAR?? agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy, American Journal of Physiology-Endocrinology and Metabolism, vol.272, issue.5, pp.790-799, 2011.
DOI : 10.1016/S0014-5793(00)01570-2

G. Cavalli and C. A. Dinarello, Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies, Rheumatology, vol.156, p.269, 2015.
DOI : 10.1007/s00296-010-1429-y

M. Chabaud, Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines, The journal of Immunology, vol.161, issue.1, pp.409-414, 1998.

A. Chawla, PPAR-?? dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation, Nature Medicine, vol.274, issue.1, pp.48-52, 2001.
DOI : 10.1074/jbc.274.27.19055

Z. Chen, A. Laurence, and J. J. Shea, Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation, Seminars in Immunology, vol.19, issue.6, pp.400-408, 2007.
DOI : 10.1016/j.smim.2007.10.015

N. Chiappetta and B. Gruber, The Role of Mast Cells in Osteoporosis, Seminars in Arthritis and Rheumatism, vol.36, issue.1, pp.32-36, 2006.
DOI : 10.1016/j.semarthrit.2006.03.004

C. Chizzolini, J. Dayer, and P. Miossec, Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance? Arthritis research & therapy, p.246, 2009.

S. Cohen, Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.39, issue.3, pp.614-624, 2002.
DOI : 10.1002/art.1780390704

J. R. Colca, Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer, Clinical Pharmacology & Therapeutics, vol.1, issue.4, pp.352-359, 2013.
DOI : 10.1016/j.cmet.2012.07.013

J. R. Colca, Identification of a novel mitochondrial protein (???mitoNEET???) cross-linked specifically by a thiazolidinedione photoprobe, American Journal of Physiology-Endocrinology and Metabolism, vol.286, issue.2, pp.252-60, 2004.
DOI : 10.1210/endo.139.12.6364

L. F. Da-rocha-junior, PPAR? Agonists in Adaptive Immunity: What Do Immune Disorders and Their Models Have to Tell Us? PPAR research, pp.519724-519733, 2013.

D. Daoussis, A. P. Andonopoulos, and S. N. Liossis, Wnt Pathway and IL-17: Novel Regulators of Joint Remodeling in Rheumatic Diseases. Looking Beyond the RANK-RANKL-OPG Axis, Seminars in Arthritis and Rheumatism, vol.39, issue.5, 2008.
DOI : 10.1016/j.semarthrit.2008.10.008

C. Deal, Bone Loss in Rheumatoid Arthritis: Systemic, Periarticular, and Focal, Current Rheumatology Reports, vol.13, issue.3, pp.231-237, 2012.
DOI : 10.1038/nm1538

B. Desvergne and W. Wahli, Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism, Endocrine Reviews, vol.20, issue.5, pp.649-688, 1999.
DOI : 10.1210/er.20.5.649

W. C. Dougall, RANK is essential for osteoclast and lymph node development. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism, pp.132412-2424, 1999.

A. Dudeck, Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function, European Journal of Immunology, vol.203, issue.7, pp.1883-1893, 2011.
DOI : 10.1084/jem.20052288

P. Escher and W. Wahli, Peroxisome proliferator-activated receptors: insight into multiple cellular functions, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.448, issue.2, pp.121-138, 2000.
DOI : 10.1016/S0027-5107(99)00231-6

S. Fadda, Serum levels of osteoprotegerin and RANKL in patients with rheumatoid arthritis and their relation to bone mineral density and disease activity, The Egyptian Rheumatologist, vol.37, issue.1, pp.1-6, 2015.
DOI : 10.1016/j.ejr.2014.06.001

H. Fahmi, Peroxisome proliferator-activated receptor ? activators inhibit interleukin-1?-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes, Arthritis & Rheumatism, vol.5, issue.3, pp.595-607, 2001.
DOI : 10.1038/372798a0

F. Féger, The role of mast cells in host defense and their subversion by bacterial pathogens, Trends in Immunology, vol.23, issue.3, pp.151-158, 2002.
DOI : 10.1016/S1471-4906(01)02156-1

L. A. Fitzpatrick, Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss, Proceedings of the National Academy of Sciences, vol.65, issue.4, pp.6027-6032, 2003.
DOI : 10.1007/s002239900697

J. E. Fonseca, Interleukin-6 as a key player in systemic inflammation and joint destruction, Autoimmunity Reviews, vol.8, issue.7, pp.538-542, 2009.
DOI : 10.1016/j.autrev.2009.01.012

M. Francois, Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element, The Journal of biological chemistry, issue.27, pp.27928411-28418, 2004.

J. Fruchart, Peroxisome proliferator-activated receptor-alpha (PPAR??): At the crossroads of obesity, diabetes and cardiovascular disease, Atherosclerosis, vol.205, issue.1, pp.1-8, 2009.
DOI : 10.1016/j.atherosclerosis.2009.03.008

S. J. Galli and M. Tsai, IgE and mast cells in allergic disease, Nature Medicine, vol.20, issue.5, pp.693-704, 2012.
DOI : 10.1016/S0167-5699(99)01535-2

S. J. Galli, N. Borregaard, and T. A. Wynn, Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils, Nature Immunology, vol.162, issue.11, pp.1035-1044, 2011.
DOI : 10.4161/epi.6.3.14017

K. Ganeshan and P. J. Bryce, Regulatory T Cells Enhance Mast Cell Production of IL-6 via Surface-Bound TGF-??, The Journal of Immunology, vol.188, issue.2, pp.594-603, 1950.
DOI : 10.4049/jimmunol.1102389

T. M. Garcia-bates, Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation, Journal of immunology, issue.11, pp.1836903-6912, 1950.

L. Gelman, J. C. Fruchart, and J. Auwerx, An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer, Cellular and Molecular Life Sciences, vol.55, issue.7, pp.6-7932, 1999.
DOI : 10.1007/s000180050345

C. Giaginis, A. Giagini, and S. Theocharis, Peroxisome proliferator-activated receptor-?? (PPAR-??) ligands as potential therapeutic agents to treat arthritis, Pharmacological Research, vol.60, issue.3, pp.160-169, 2009.
DOI : 10.1016/j.phrs.2009.02.005

J. M. Gimble, Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells, Mol Pharmacol, vol.50, issue.5, pp.1087-1094, 1996.

C. K. Glass and S. Ogawa, Combinatorial roles of nuclear receptors in inflammation and immunity, Nature Reviews Immunology, vol.19, issue.1, pp.44-55, 2006.
DOI : 10.1210/me.2004-0529

S. R. Goldring, Pathogenesis of bone and cartilage destruction in rheumatoid arthritis, Rheumatology, vol.42, issue.90002, pp.11-17, 2003.
DOI : 10.1093/rheumatology/keg327

I. Gotis-graham and H. P. Mcneil, Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression, Arthritis & Rheumatism, vol.154, issue.3, pp.479-489, 1997.
DOI : 10.1177/37.4.2647838

E. M. Gravallese, Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor, Arthritis & Rheumatism, vol.43, issue.2, pp.250-258, 2000.
DOI : 10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P

A. Grey, Skeletal consequences of thiazolidinedione therapy, Osteoporosis International, vol.9, issue.Suppl 1, pp.129-137, 2008.
DOI : 10.4158/EP.9.6.544

F. Guillemin, Prevalence of rheumatoid arthritis in France: 2001, Annals of the Rheumatic Diseases, vol.64, issue.10, pp.1427-1430, 2001.
DOI : 10.1136/ard.2004.029199

S. G. Harris and R. P. Phipps, The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis, European Journal of Immunology, vol.7, issue.4, pp.1098-1105, 2001.
DOI : 10.1080/09629359891216

M. Hashizume, Tocilizumab, A Humanized Anti-IL-6R Antibody, as an Emerging Therapeutic Option for Rheumatoid Arthritis: Molecular and Cellular Mechanistic Insights, International Reviews of Immunology, vol.65, issue.1, pp.265-279, 2015.
DOI : 10.1016/j.biologicals.2010.07.002

D. R. Haynes, Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls, Rheumatology, vol.42, issue.1, pp.123-134, 2003.
DOI : 10.1093/rheumatology/keg047

P. Herrak, Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis, Arthritis & Rheumatism, vol.44, issue.Suppl 6, pp.2327-2337, 2004.
DOI : 10.1007/s002960000080

J. N. Hoes, I. E. Bultink, and W. F. Lems, Management of osteoporosis in rheumatoid arthritis patients, Expert Opinion on Pharmacotherapy, vol.45, issue.6, pp.559-571, 2015.
DOI : 10.1093/rheumatology/ket468

J. Holoshitz, The rheumatoid arthritis HLA???DRB1 shared epitope, Current Opinion in Rheumatology, vol.22, issue.3, pp.293-298, 2010.
DOI : 10.1097/BOR.0b013e328336ba63

A. J. Hueber, Cutting Edge: Mast Cells Express IL-17A in Rheumatoid Arthritis Synovium, The Journal of Immunology, vol.184, issue.7, pp.3336-3340, 1950.
DOI : 10.4049/jimmunol.0903566

N. Ipseiz, Adopted orphans as regulators of inflammation, immunity and skeletal homeostasis, Swiss Medical Weekly, vol.144, p.14055, 2014.
DOI : 10.4414/smw.2014.14055

A. M. Irani, Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. The journal of histochemistry and cytochemistry : official journal of the, Histochemistry Society, issue.10, pp.371509-1515, 1989.

I. Issemann and S. Green, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, Nature, vol.347, issue.6294, pp.645-650, 1990.
DOI : 10.1038/347645a0

M. C. Jamur and C. Oliver, Origin, maturation and recruitment of mast cell precursors, Frontiers in bioscience, vol.3, pp.1390-1406, 2011.

C. Jiang, A. T. Ting, and B. Seed, PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines, Nature, issue.6662, pp.39182-86, 1998.

Y. Jiang, A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores, Arthritis & Rheumatism, vol.43, issue.5, pp.1001-1009, 2000.
DOI : 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P

L. A. Joosten, IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation, Journal of immunology, issue.9, pp.1635049-5055, 1950.

N. Kambe, Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body, Blood, vol.103, issue.3, pp.860-867, 2004.
DOI : 10.1182/blood-2003-04-1160

Y. Katz, O. Nadiv, and Y. Beer, Interleukin-17 enhances tumor necrosis factor ?-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: A possible role as a ?fine-tuning cytokine? in inflammation processes, Arthritis & Rheumatism, vol.164, issue.9, pp.2176-2184, 2001.
DOI : 10.4049/jimmunol.164.9.4783

J. Kay and K. S. Upchurch, ACR/EULAR 2010 rheumatoid arthritis classification criteria, Rheumatology, vol.62, issue.9, pp.5-9, 2012.
DOI : 10.1002/art.27580

URL : https://academic.oup.com/rheumatology/article-pdf/51/suppl_6/vi5/5056206/kes279.pdf

S. Kersten, B. Desvergne, and W. Wahli, Roles of PPARs in health and disease, Nature, vol.402, issue.6785, pp.421-424, 2000.
DOI : 10.2337/diabetes.48.7.1466

D. J. Kim, Peroxisome Proliferator-activated Receptor-??/?? Inhibits Epidermal Cell Proliferation by Down-regulation of Kinase Activity, Journal of Biological Chemistry, vol.280, issue.10, pp.9519-9527, 2005.
DOI : 10.1074/jbc.M413808200

G. W. Kim, IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future, Archives of Pharmacal Research, vol.371, issue.Suppl 10, pp.575-584, 2015.
DOI : 10.1016/S0140-6736(08)60454-7

H. Kitaura, Immunological reaction in TNF-?-mediated osteoclast formation and bone resorption in vitro and in vivo, Clinical and Developmental Immunology, issue.2, pp.2013181849-2013181857, 2013.

L. Klotz, The nuclear receptor PPAR?? selectively inhibits Th17 differentiation in a T cell???intrinsic fashion and suppresses CNS autoimmunity, The Journal of Experimental Medicine, vol.524, issue.10, pp.2079-2089, 2009.
DOI : 10.1038/nature06878

URL : https://hal.archives-ouvertes.fr/pasteur-00509630

H. Knüpfer and R. Preiss, sIL-6R: more than an agonist? Immunology and cell biology, pp.87-91, 2008.

Y. Kochi, A. Suzuki, and K. Yamamoto, Genetic basis of rheumatoid arthritis: a current review. Biochemical and biophysical research communications, pp.254-262, 2014.

M. I. Koenders, Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1??, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: Rationale for combination treatment during arthritis, Arthritis & Rheumatism, vol.58, issue.Suppl I, pp.632329-2339, 2011.
DOI : 10.1136/ard.58.2008.i40

N. Komatsu, Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis, Nature Medicine, vol.20, issue.1, pp.62-68, 2014.
DOI : 10.1016/S1534-5807(02)00369-6

I. Koné-paut and C. Galeotti, Anakinra for cryopyrin-associated periodic syndrome. Expert review of clinical immunology, pp.7-18, 2014.

P. J. Koshy, Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines, Annals of the Rheumatic Diseases, vol.61, issue.8, pp.61704-713, 2002.
DOI : 10.1136/ard.61.8.704

B. P. Kota, T. H. Huang, and B. D. Roufogalis, An overview on biological mechanisms of PPARs, Pharmacological Research, vol.51, issue.2, pp.85-94, 2005.
DOI : 10.1016/j.phrs.2004.07.012

S. Kotake, Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients, Arthritis & Rheumatism, vol.247, issue.5, pp.1003-1012, 2001.
DOI : 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#

M. Koufany, Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis, Arthritis Research & Therapy, vol.10, issue.1, p.6, 2008.
DOI : 10.1186/ar2354

URL : https://hal.archives-ouvertes.fr/hal-01715309

C. L. Langrish, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, The Journal of Experimental Medicine, vol.71, issue.2, pp.233-240, 2005.
DOI : 10.1038/nri802

O. P. Lazarenko, Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged Bone, Endocrinology, vol.148, issue.6, pp.2669-2680, 2007.
DOI : 10.1210/en.2006-1587

L. Li, IL-17 produced by neutrophils regulates IFN-?????mediated neutrophil migration in mouse kidney ischemia-reperfusion injury, Journal of Clinical Investigation, vol.120, issue.1, pp.331-342, 2010.
DOI : 10.1172/JCI38702DS1

P. Li, E. M. Schwarz, R. J. O-'keefe, L. Ma, and B. F. Boyce, RANK Signaling Is Not Required for TNF??-Mediated Increase in CD11bhi Osteoclast Precursors but Is Essential for Mature Osteoclast Formation in TNF??-Mediated Inflammatory Arthritis, Journal of Bone and Mineral Research, vol.43, issue.2, pp.207-213, 2004.
DOI : 10.4049/jimmunol.164.11.5990

P. Li, E. M. Schwarz, R. J. O-'keefe, L. Ma, and R. J. Looney, Systemic tumor necrosis factor ? mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor ?-transgenic mice, Arthritis & Rheumatism, vol.23, issue.1, pp.265-276, 2004.
DOI : 10.4049/jimmunol.165.1.49

H. Lim, Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism, pp.131561-1574, 1999.

J. Liu, Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice, Nature Medicine, vol.59, issue.8, pp.940-945, 2009.
DOI : 10.1016/S0002-9440(10)62055-X

Y. K. Loke, S. Singh, and C. D. Furberg, Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis, Canadian Medical Association Journal, vol.180, issue.1, pp.32-39, 2009.
DOI : 10.1503/cmaj.080486

L. Lu, Mast cells are essential intermediaries in regulatory T-cell tolerance, Nature, vol.174, issue.7106, pp.997-1002, 2006.
DOI : 10.4049/jimmunol.174.4.1783

E. Lubberts, IL-17 Promotes Bone Erosion in Murine Collagen-Induced Arthritis Through Loss of the Receptor Activator of NF-??B Ligand/Osteoprotegerin Balance, The Journal of Immunology, vol.170, issue.5, pp.2655-2662, 2003.
DOI : 10.4049/jimmunol.170.5.2655

E. Lubberts, Reduction of interleukin???17???induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin???4, Arthritis & Rheumatism, vol.43, issue.6, pp.1300-1306, 2000.
DOI : 10.1002/1529-0131(200006)43:6<1300::AID-ANR12>3.0.CO;2-D

S. Luquet, Peroxisome proliferator-activated receptor ?? controls muscle development and oxidative capability, The FASEB Journal, vol.17, issue.15, pp.2299-2301, 2003.
DOI : 10.1096/fj.03-0269fje

N. J. Magarinos, Mast Cell-Restricted, Tetramer-Forming Tryptases Induce Aggrecanolysis in Articular Cartilage by Activating Matrix Metalloproteinase-3 and -13 Zymogens, The Journal of Immunology, vol.191, issue.3, pp.1911404-1412, 1950.
DOI : 10.4049/jimmunol.1300856

R. Malaviya, Mast cell phagocytosis of FimH-expressing enterobacteria, The journal of Immunology, vol.152, issue.4, pp.1907-1914, 1994.

M. Man, Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. Functions of the Peroxisome Proliferator-Activated Receptor (PPAR) alpha and beta in Skin Homeostasis, Epithelial Repair, and Morphogenesis, vol.128, issue.2, pp.370-377, 2008.

G. Mbalaviele, Activation of Peroxisome Proliferator-activated Receptor-?? Pathway Inhibits Osteoclast Differentiation, Journal of Biological Chemistry, vol.9, issue.19, pp.14388-14393, 2000.
DOI : 10.1038/22572

H. F. Mcfarland and R. Martin, Multiple sclerosis: a complicated picture of autoimmunity, Nature Immunology, vol.96, issue.9, pp.913-919, 2007.
DOI : 10.1016/j.jns.2005.03.011

H. P. Mcneil and I. Gotis-graham, Human mast cell subsets - distinct functions in inflammation?, Inflammation Research, vol.49, issue.1, pp.3-7, 2000.
DOI : 10.1007/PL00012386

L. Michalik, International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors, Pharmacological Reviews, vol.58, issue.4, pp.726-741, 2006.
DOI : 10.1124/pr.58.4.5

URL : https://hal.archives-ouvertes.fr/hal-00188041

J. Moitra, Life without white fat: a transgenic mouse Peroxisome proliferatoractivated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism, Cytokine, vol.12, issue.203, pp.3168-3181, 1998.

D. Moulin, Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1?-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor ?/?-dependent mechanism, Arthritis & Rheumatism, vol.64, issue.3, pp.759-769, 2005.
DOI : 10.1161/01.CIR.102.15.1834

URL : https://hal.archives-ouvertes.fr/hal-01715364

K. Nadra, PPAR?? in Placental Angiogenesis, Endocrinology, vol.151, issue.10, pp.4969-4981, 2010.
DOI : 10.1210/en.2010-0131

S. Nakae, Mast cells enhance T cell activation: Importance of mast cell-derived TNF, Proceedings of the National Academy of Sciences of the United States of America, pp.6467-6472, 2005.
DOI : 10.1084/jem.184.4.1397

S. Nakae, Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice, The Journal of Immunology, vol.171, issue.11, pp.6173-6177, 2003.
DOI : 10.4049/jimmunol.171.11.6173

T. Nakano, Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell- deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells, Journal of Experimental Medicine, vol.162, issue.3, pp.1025-1043, 1985.
DOI : 10.1084/jem.162.3.1025

J. G. Neels and P. A. Grimaldi, Physiological Functions of Peroxisome Proliferator-Activated Receptor ??, Physiological Reviews, vol.268, issue.3, pp.795-858, 2014.
DOI : 10.1038/sj.onc.1209160

K. W. Nettles and G. L. Greene, LIGAND CONTROL OF COREGULATOR RECRUITMENT TO NUCLEAR RECEPTORS, Annual Review of Physiology, vol.67, issue.1, pp.309-333, 2005.
DOI : 10.1146/annurev.physiol.66.032802.154710

K. Nistala, Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment, Proceedings of the National Academy of Sciences of the United States of America, pp.14751-14756, 2010.
DOI : 10.1046/j.1365-2249.2001.01665.x

C. Noli and A. Miolo, The mast cell in wound healing, Veterinary Dermatology, vol.12, issue.6, pp.303-313, 2001.
DOI : 10.1111/j.1365-3164.1997.tb00267.x

K. Ohshima, M. Mogi, and M. Horiuchi, in Vascular Inflammation, International Journal of Vascular Medicine, vol.180, issue.1, pp.2012508416-2012508425, 2012.
DOI : 10.1136/bmj.c5333

M. Ohtsuji, IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel Fc??RIIB-deficient rheumatoid arthritis mouse model, Modern Rheumatology, vol.66, issue.1, pp.270-277, 2015.
DOI : 10.1002/art.38202

H. Okamoto, Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis, Clin Exp Rheumatol, vol.23, issue.3, pp.323-330, 2005.

N. Olsson, A. K. Ulfgren, and G. Nilsson, Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients, Annals of the Rheumatic Diseases, vol.60, issue.3, pp.187-193, 2001.
DOI : 10.1136/ard.60.3.187

K. A. Papp, Brodalumab, an Anti???Interleukin-17???Receptor Antibody for Psoriasis, New England Journal of Medicine, vol.366, issue.13, pp.1181-1189, 2012.
DOI : 10.1056/NEJMoa1109017

D. D. Patel, Effect of IL-17A blockade with secukinumab in autoimmune diseases, Annals of the Rheumatic Diseases, vol.72, issue.suppl 2, pp.116-139, 2013.
DOI : 10.1136/annrheumdis-2012-202371

A. I. Petra, Spectrum of mast cell activation disorders. Expert review of clinical immunology, pp.729-739, 2014.

A. R. Pettit, TRANCE/RANKL Knockout Mice Are Protected from Bone Erosion in a Serum Transfer Model of Arthritis, The American Journal of Pathology, vol.159, issue.5, pp.1689-1699, 2001.
DOI : 10.1016/S0002-9440(10)63016-7

P. E. Poleni, Agonists of peroxisome proliferators-activated receptors (PPAR) ??, ??/?? or ?? reduce transforming growth factor (TGF)-??-induced proteoglycans' production in chondrocytes, Osteoarthritis and Cartilage, vol.15, issue.5, pp.493-505, 2007.
DOI : 10.1016/j.joca.2006.10.009

P. Poncet, M. Arock, and B. David, T cell hybridomas by human mast cells through superantigen presentation, Journal of Leukocyte Biology, vol.66, issue.1, pp.105-112, 1999.
DOI : 10.1002/jlb.66.1.105

K. Redlich, Osteoclasts are essential for TNF-?????mediated joint destruction, Journal of Clinical Investigation, vol.110, issue.10, pp.1419-1427, 2002.
DOI : 10.1172/JCI0215582

C. V. Rizos, How safe is the use of thiazolidinediones in clinical practice? Expert opinion on drug safety, pp.15-32, 2009.

E. D. Rosen, C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism, pp.22-26, 2002.

E. D. Rosen, PPAR?? Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro, Molecular Cell, vol.4, issue.4, pp.611-617, 1999.
DOI : 10.1016/S1097-2765(00)80211-7

M. Rossini, Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis, Bone, vol.49, issue.4, pp.880-885, 2011.
DOI : 10.1016/j.bone.2011.07.004

A. Ruyssen-witrand, New insights into the genetics of immune responses in rheumatoid arthritis, Tissue Antigens, vol.25, issue.Suppl 7, pp.105-118, 2012.
DOI : 10.1002/jcc.20084

URL : https://hal.archives-ouvertes.fr/inserm-00730978

P. A. Sarafidis and G. L. Bakris, Protection of the kidney by thiazolidinediones: An assessment from bench to bedside, Kidney International, vol.70, issue.7, pp.1223-1233, 2006.
DOI : 10.1038/sj.ki.5001620

O. Schmetzer, Murine and human mast cell progenitors, European Journal of Pharmacology, vol.778, 2015.
DOI : 10.1016/j.ejphar.2015.07.016

E. Schmidt and D. Zillikens, Pemphigoid diseases. Generalised bone loss in patients with early rheumatoid arthritis, pp.320-332, 2013.
DOI : 10.1016/s0140-6736(12)61140-4

A. V. Schwartz, Thiazolidinedione Use and Bone Loss in Older Diabetic Adults, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.9, pp.3349-3354, 2006.
DOI : 10.1210/jc.2005-2226

L. B. Schwartz, Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis, New England Journal of Medicine, vol.316, issue.26, pp.3161622-1626, 1987.
DOI : 10.1056/NEJM198706253162603

S. Seitz, Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis, Osteoporosis International, vol.15, issue.Suppl 1, pp.2325-2334, 2013.
DOI : 10.1359/jbmr.2000.15.1.13

D. Shahin, Effect of Peroxisome Proliferator-Activated Receptor Gamma Agonist (Pioglitazone) and Methotrexate on Disease Activity in Rheumatoid Arthritis (Experimental and Clinical Study), Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, vol.4, issue.4, pp.1-10, 2011.
DOI : 10.4137/CMAMD.S5951

H. A. Simmons and L. G. Raisz, Effects of acid and basic fibroblast growth factor and heparin on resorption of cultured fetal rat long bones, Journal of Bone and Mineral Research, vol.111, issue.Suppl. 2, pp.1301-1305, 1991.
DOI : 10.1002/jbmr.5650061206

M. A. Simonin, PPAR-?? ligands modulate effects of LPS in stimulated rat synovial fibroblasts, American Journal of Physiology-Cell Physiology, vol.275, issue.1, pp.125-158, 2002.
DOI : 10.1002/art.1780370601

N. A. Sims, Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis, Arthritis & Rheumatism, vol.3, issue.7, pp.2338-2346, 2004.
DOI : 10.1111/j.1476-5381.1996.tb15972.x

L. A. Solt, Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand, Nature, vol.2, issue.7344, pp.472491-494, 2011.
DOI : 10.1002/pro.5560020404

M. A. Sorocéanu, Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis, Journal of Endocrinology, vol.183, issue.1, pp.203-216, 2004.
DOI : 10.1677/joe.1.05723

G. Steiner, Cytokine production by synovial T cells in rheumatoid arthritis, Rheumatology, vol.38, issue.3, pp.202-213, 1999.
DOI : 10.1093/rheumatology/38.3.202

E. Stelekati, Mast Cell-Mediated Antigen Presentation Regulates CD8+ T Cell Effector Functions, Immunity, vol.31, issue.4, pp.665-676, 2009.
DOI : 10.1016/j.immuni.2009.08.022

K. Still, The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo, Calcified Tissue International, vol.302, issue.4, pp.285-292, 2008.
DOI : 10.1007/s00223-008-9175-9

S. G. Suke, Anti-arthritic and anti-inflammatory activity of combined pioglitazone and prednisolone on adjuvant-induced arthritis, European Journal of Pharmacology, vol.718, issue.1-3, pp.1-357, 2013.
DOI : 10.1016/j.ejphar.2013.09.019

P. F. Sumariwalla, Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717, Rheumatology, vol.19, issue.9, pp.32-38, 2009.
DOI : 10.1161/01.ATV.19.9.2094

H. Suto, Mast Cell-Associated TNF Promotes Dendritic Cell Migration, The Journal of Immunology, vol.176, issue.7, pp.4102-4112, 2006.
DOI : 10.4049/jimmunol.176.7.4102

J. Suurmond, T cells through antigen-dependent interactions, European Journal of Immunology, vol.94, issue.7, pp.1758-1768, 2013.
DOI : 10.1073/pnas.0913054107

J. Suurmond, Mast cells in rheumatic disease, European Journal of Pharmacology, vol.778, 2015.
DOI : 10.1016/j.ejphar.2015.03.085

J. Suurmond, Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Annals of the rheumatic diseases, pp.2014-205562, 2014.

W. Tang, Thiazolidinediones Regulate Adipose Lineage Dynamics, Cell Metabolism, vol.14, issue.1, pp.116-122, 2011.
DOI : 10.1016/j.cmet.2011.05.012

URL : https://doi.org/10.1016/j.cmet.2011.05.012

P. C. Taylor and M. Feldmann, Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis, Nature Reviews Rheumatology, vol.60, issue.10, pp.578-582, 2009.
DOI : 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.0.CO;2-A

L. Teboul, Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells, The Journal of biological chemistry, vol.270, issue.47, pp.28183-28187, 1995.

T. C. Theoharides, P. Valent, and C. Akin, Mast Cells, Mastocytosis, and Related Disorders, Mast Cells, Mastocytosis, and Related Disorders, pp.163-172, 2015.
DOI : 10.1056/NEJMra1409760

P. Tontonoz, E. Hu, and B. M. Spiegelman, Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor, Cell, issue.7, pp.791147-1156, 1994.

M. Urb and D. C. Sheppard, The Role of Mast Cells in the Defence against Pathogens, PLoS Pathogens, vol.65, issue.4, p.1002619, 2012.
DOI : 10.1371/journal.ppat.1002619.g001

P. Valent, Diagnostic criteria and classification of mastocytosis: a consensus proposal, Leukemia research, pp.603-625, 2001.
DOI : 10.1016/S0145-2126(01)00038-8

P. Valent, Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria, European Journal of Clinical Investigation, vol.95, issue.6, pp.435-453, 2007.
DOI : 10.1016/S0889-8588(05)70298-7

URL : https://hal.archives-ouvertes.fr/hal-00282493

L. G. Van-baarsen, Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?, Arthritis Research & Therapy, vol.64, issue.4, p.426, 2014.
DOI : 10.1002/art.33396

W. B. Van-den-berg, Arguments for interleukin 1 as a target in chronic arthritis, Annals of the Rheumatic Diseases, vol.59, issue.90001, pp.81-85, 2000.
DOI : 10.1136/ard.59.suppl_1.i81

E. Van-der-veer, High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis, Allergy, vol.49, issue.3, pp.431-438, 2012.
DOI : 10.1016/j.bone.2011.07.004

P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes???a meta-analysis, Osteoporosis International, vol.8, issue.Suppl 1, pp.427-444, 2007.
DOI : 10.1016/S1695-4033(00)77393-0

M. V. Volin and S. Shahrara, Role of TH-17 Cells in Rheumatic and Other Autoimmune Diseases, Rheumatology : Current Research, vol.01, issue.01, p.1, 2011.
DOI : 10.4172/2161-1149.1000104

M. C. Walsh and Y. Choi, Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Frontiers in immunology, vol.5, p.511, 2014.

N. C. Walsh and E. M. Gravallese, Bone remodeling in rheumatic disease: a question of balance, Immunological Reviews, vol.47, issue.Suppl, pp.301-312, 2010.
DOI : 10.4049/jimmunol.170.5.2655

W. Wang, The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis, Rheumatology International, vol.46, issue.Suppl 2, pp.887-893, 2012.
DOI : 10.1093/rheumatology/kem285

U. Wingren and L. Enerbäck, Mucosal mast cells of the rat intestine: a re-evaluation of fixation and staining properties, with special reference to protein blocking and solubility of the granular glycosaminoglycan, The Histochemical Journal, vol.252, issue.6, pp.571-582, 1983.
DOI : 10.1177/25.9.71326

B. U. Wintroub, Morphologic and Functional Evidence for Release of Mast-Cell Products in Bullous Pemphigoid, New England Journal of Medicine, vol.298, issue.8, pp.417-421, 1978.
DOI : 10.1056/NEJM197802232980803

M. B. Wright, Minireview: Challenges and opportunities in development of PPAR agonists. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis, pp.1756-1768, 2014.

Z. Wu, P. Puigserver, and B. M. Spiegelman, Transcriptional activation of adipogenesis, Current Opinion in Cell Biology, vol.11, issue.6, pp.689-694, 1999.
DOI : 10.1016/S0955-0674(99)00037-X

X. O. Yang, T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors ROR?? and ROR??, Immunity, vol.28, issue.1, pp.29-39, 2008.
DOI : 10.1016/j.immuni.2007.11.016

URL : https://doi.org/10.1016/j.immuni.2007.11.016

X. Yu, A. Kasprick, and F. Petersen, Revisiting the role of mast cells in autoimmunity, Autoimmunity Reviews, vol.14, issue.9, pp.751-759, 2015.
DOI : 10.1016/j.autrev.2015.04.008

F. Zandbergen and J. Plutzky, PPARalpha in atherosclerosis and inflammation, Biochim Biophys Acta, issue.8, pp.1771972-982, 2007.

G. Zhang, Rosiglitazone inhibits HMC-1 cell migration and adhesion through a peroxisome proliferator-activated receptor gamma-dependent mechanism, Iranian journal of allergy, asthma, and immunology, vol.13, issue.1, pp.11-18, 2014.

J. Zupan, M. Jeras, and J. Marc, Osteoimmunology and the influence of proinflammatory cytokines on osteoclasts, Biochemia medica, vol.23, issue.1, pp.43-63, 2013.

J. Zwerina, TNF-induced structural joint damage is mediated by IL-1, Proceedings of the National Academy of Sciences of the United States of America, pp.11742-11747, 2007.
DOI : 10.1084/jem.187.9.1463